BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1039 related articles for article (PubMed ID: 17710731)

  • 1. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    Blank SK; McCartney CR; Helm KD; Marshall JC
    Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome.
    Blank SK; McCartney CR; Marshall JC
    Hum Reprod Update; 2006; 12(4):351-61. PubMed ID: 16670102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.
    Baskind NE; Balen AH
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():80-97. PubMed ID: 27137106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothesis: aberrant puberty and the Stein-Leventhal syndrome.
    Mechanick JI; Futterweit W
    Int J Fertil; 1984; 29(1):35-8. PubMed ID: 6146582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gonadotropic axis in hyperandrogenic adolescents.
    Taylor AE
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1281-4. PubMed ID: 11117670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology.
    Balen A
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):685-706. PubMed ID: 15380141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine dysfunction in polycystic ovary syndrome.
    Burt Solorzano CM; Beller JP; Abshire MY; Collins JS; McCartney CR; Marshall JC
    Steroids; 2012 Mar; 77(4):332-7. PubMed ID: 22172593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
    Allon MA; Leach RE; Dunbar J; Diamond MP
    Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of changing pulse frequency in the regulation of ovulation.
    Marshall JC; Griffin ML
    Hum Reprod; 1993 Nov; 8 Suppl 2():57-61. PubMed ID: 8276970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine aspects of polycystic ovary syndrome.
    Marshall JC; Eagleson CA
    Endocrinol Metab Clin North Am; 1999 Jun; 28(2):295-324. PubMed ID: 10352920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.